Eli Lilly and Bayer Warn Germany’s Pharma Policies Risk Investment
Eli Lilly and Bayer have criticized Germany’s spending policies on innovative medicines, warning they could undermine the country’s attractiveness for pharmaceutical investment, according to a Financial Times report.
The Financial Times reports that pharmaceutical giants Eli Lilly and Bayer have publicly criticized Germany's approach to financing innovative medicines. The companies argue that current policies may deter investment in the country's pharmaceutical sector.
Both firms cautioned that restrictive spending measures could erode Germany's competitive edge as a hub for life sciences and drug development. The criticism highlights growing tension between the industry and policymakers over healthcare spending priorities.
Source: First Squawk